These findings mirror earlier success observed in a China-only late-stage study, providing a consistent clinical signal for the drug often referred to as ris-rez. The data strengthen the case for accelerated regulatory pathways as the company looks to expand its oncology footprint.

GSK is currently managing late-stage trials for ris-rez targeting advanced lung and prostate cancers. Looking ahead, the pharmaceutical giant intends to broaden its investigative scope by initiating studies in earlier stages of these diseases to determine if the drug can offer more durable outcomes for a wider patient population.